Alan N. Houghton

Q: What Schools Are Affiliated With Alan N. Houghton

Alan N. Houghton is affiliated with the following schools: Rockefeller University, Massachusetts Institute of Technology, Cornell University, University of California, San Francisco, Columbia University, University of Pennsylvania

Alan N. Houghton's AcademicInfluence.com Rankings

Alan N. Houghton

Philosophy

#7032

World Rank

#10179

Historical Rank

Logic

#4108

World Rank

#5359

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Alan N. Houghton's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Alan N. Houghton Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Alan N. Houghton's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. (2001) (2651)
Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. (1999) (729)
Monoclonal antibody therapy of cancer. (1990) (626)
Concomitant Tumor Immunity to a Poorly Immunogenic Melanoma Is Prevented by Regulatory T Cells (2004) (595)
Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. (1985) (565)
Focus on melanoma. (2002) (522)
Receptor-Mediated Uptake of Antigen/Heat Shock Protein Complexes Results in Major Histocompatibility Complex Class I Antigen Presentation via Two Distinct Processing Pathways (2000) (455)
Cancer antigens: immune recognition of self and altered self (1994) (438)
Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma (1992) (435)
A new American Joint Committee on Cancer staging system for cutaneous melanoma (2000) (428)
An Evidence‐based Staging System for Cutaneous Melanoma 1 (2004) (420)
Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets (1982) (350)
Fc receptors are required in passive and active immunity to melanoma. (1998) (346)
Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. (2003) (335)
Homozygous deletions within human chromosome band 9p21 in melanoma. (1992) (323)
Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment. (2011) (319)
Coupling and Uncoupling of Tumor Immunity and Autoimmunity (1999) (260)
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. (2006) (259)
Tumor immunity and autoimmunity induced by immunization with homologous DNA. (1998) (243)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation (2010) (240)
Surface antigens of melanoma and melanocytes. Specificity of induction of Ia antigens by human gamma-interferon (1984) (238)
Classification and subtype prediction of adult soft tissue sarcoma by functional genomics. (2003) (227)
Heteroclitic Immunization Induces Tumor Immunity (1998) (224)
Heterogeneity in surface antigen and glycoprotein expression of cell lines derived from different melanoma metastases of the same patient. Implications for the study of tumor antigens (1981) (219)
Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. (2003) (219)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis (2009) (217)
Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21. (2000) (213)
Prognostic factors in patients with metastatic malignant melanoma: A multivariate analysis (1993) (213)
Implicating a role for immune recognition of self in tumor rejection: passive immunization against the brown locus protein (1995) (209)
Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity. (2006) (209)
A Role for Dipeptidyl Peptidase IV in Suppressing the Malignant Phenotype of Melanocytic Cells (1999) (205)
Immunity against cancer: lessons learned from melanoma. (2001) (204)
Immunization of metastatic breast cancer patients with a fully synthetic globo H conjugate: A phase I trial (2001) (190)
The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product (1990) (189)
Autoimmune response of patients with paraneoplastic cerebellar degeneration to a Purkinje cell cytoplasmic protein antigen (1985) (185)
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70. (2000) (183)
Induction of pigmentation in mouse fibroblasts by expression of human tyrosinase cDNA (1989) (180)
Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guérin. (1999) (180)
A marker for neoplastic progression of human melanocytes is a cell surface ectopeptidase (1993) (180)
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity1 (2006) (176)
Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity. (1996) (174)
Generation of human monoclonal antibodies reactive with cellular antigens. (1983) (168)
Intracellular sorting and targeting of melanosomal membrane proteins: identification of signals for sorting of the human brown locus protein, gp75 (1995) (168)
Classification of clear-cell sarcoma as a subtype of melanoma by genomic profiling. (2003) (167)
Phase I trial of a mouse monoclonal antibody against GD3 ganglioside in patients with melanoma: induction of inflammatory responses at tumor sites. (1988) (164)
Phenotypic heterogeneity of melanoma. Relation to the differentiation program of melanoma cells (1987) (161)
Surface antigens of melanomas and melanocytes defined by mouse monoclonal antibodies: specificity analysis and comparison of antigen expression in cultured cells and tissues. (1985) (159)
Vaccination with human tyrosinase DNA induces antibody responses in dogs with advanced melanoma. (2006) (157)
Cutting Edge: OX40 Agonists Can Drive Regulatory T Cell Expansion if the Cytokine Milieu Is Right (2009) (151)
Phase II study of temozolomide plus thalidomide for the treatment of metastatic melanoma. (2003) (140)
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype (2012) (136)
Role for dipeptidyl peptidase IV in tumor suppression of human non small cell lung carcinoma cells (2004) (135)
Immune recognition of self in immunity against cancer. (2004) (134)
GITR Pathway Activation Abrogates Tumor Immune Suppression through Loss of Regulatory T-cell Lineage Stability (2013) (133)
CTLA-4 blockade in combination with xenogeneic DNA vaccines enhances T-cell responses, tumor immunity and autoimmunity to self antigens in animal and cellular model systems. (2004) (130)
New TNM melanoma staging system: linking biology and natural history to clinical outcomes. (2003) (128)
Prognostic significance of peripheral blood and bone marrow tyrosinase messenger RNA in malignant melanoma. (1998) (127)
GITR Activation Induces an Opposite Effect on Alloreactive CD4+ and CD8+ T Cells in Graft-Versus-Host Disease (2004) (119)
HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. (2001) (118)
A Single Heteroclitic Epitope Determines Cancer Immunity After Xenogeneic DNA Immunization Against a Tumor Differentiation Antigen1 (2003) (117)
Stimulation of T lymphocyte proliferation by monoclonal antibodies against GD3 ganglioside. (1987) (114)
T-cell responses against tyrosinase 368-376(370D) peptide in HLA*A0201+ melanoma patients: randomized trial comparing incomplete Freund's adjuvant, granulocyte macrophage colony-stimulating factor, and QS-21 as immunological adjuvants. (2002) (111)
Detection of cell surface and intracellular antigens by human monoclonal antibodies. Hybrid cell lines derived from lymphocytes of patients with malignant melanoma (1983) (110)
Immunization with DNA coding for gp100 results in CD4 T-cell independent antitumor immunity. (2000) (110)
Immunization of melanoma patients with BEC2 anti-idiotypic monoclonal antibody that mimics GD3 ganglioside: enhanced immunogenicity when combined with adjuvant. (1996) (109)
Loss of polymorphic restriction fragments in malignant melanoma: implications for tumor heterogeneity. (1985) (109)
Temozolomide plus thalidomide in patients with brain metastases from melanoma (2005) (108)
Cyclophosphamide enhances immunity by modulating the balance of dendritic cell subsets in lymphoid organs. (2010) (108)
Evaluation of CD8+ T‐cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide (2000) (107)
Immunity to melanoma: unraveling the relation of tumor immunity and autoimmunity (2003) (105)
Self-antigen–specific CD8+ T cell precursor frequency determines the quality of the antitumor immune response (2009) (104)
Frequent p16-independent inactivation of p14ARF in human melanoma. (2008) (101)
Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. (2007) (101)
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies: identification of astrocytoma subsets. (1982) (101)
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. (1993) (101)
Differentiation antigens of melanocytes and melanoma: analysis of melanosome and cell surface markers of human pigmented cells with monoclonal antibodies. (1988) (94)
Autoimmunity and tumor immunity induced by immune responses to mutations in self (2006) (93)
Expression of disialogangliosides GD2 and GD3 on human soft tissue sarcomas (1992) (93)
Monoclonal antibody therapies–a ‘constant’ threat to cancer (2000) (92)
Optimization of a self antigen for presentation of multiple epitopes in cancer immunity. (2006) (92)
Blockade of surface-bound TGF-β on regulatory T cells abrogates suppression of effector T cell function in the tumor microenvironment (2017) (90)
Loss of heterozygosity at autosomal and X-linked loci during tumor progression in a patient with melanoma. (1987) (89)
HDM2 protein overexpression and prognosis in primary malignant melanoma. (2002) (89)
Class II histocompatibility antigen expression in human melanocytes transformed by Harvey murine sarcoma virus (Ha-MSV) and Kirsten MSV retroviruses (1986) (88)
Phase I/II study of GM-CSF DNA as an adjuvant for a multipeptide cancer vaccine in patients with advanced melanoma (2008) (86)
Stage-IV Melanoma and Pulmonary Metastases: Factors Predictive of Survival (2007) (86)
Safety and immunogenicity of a human and mouse gp100 DNA vaccine in a phase I trial of patients with melanoma. (2009) (85)
Malignant melanoma of the skin occurring during pregnancy (1981) (84)
Systemic chemotherapy. (2000) (84)
Multiple pathways to tumor immunity and concomitant autoimmunity (2002) (84)
Immunization of High-Risk Breast Cancer Patients with Clustered sTn-KLH Conjugate plus the Immunologic Adjuvant QS-21 (2007) (80)
Retrovirally Transduced Mouse Dendritic Cells Require CD4+ T Cell Help to Elicit Antitumor Immunity: Implications for the Clinical Use of Dendritic Cells1 (2000) (79)
Evidence against Ha-ras-1 involvement in sporadic and familial melanoma (1987) (78)
NCCN MELANOMA PRACTICE GUIDELINES (1998) (78)
A melanosomal membrane protein is a cell surface target for melanoma therapy. (1996) (77)
Biosynthesis and intracellular movement of the melanosomal membrane glycoprotein gp75, the human b (brown) locus product. (1991) (76)
Redundant and alternative roles for activating Fc receptors and complement in an antibody-dependent model of autoimmune vitiligo. (2002) (75)
Increased facilitated transport of dehydroascorbic acid without changes in sodium-dependent ascorbate transport in human melanoma cells. (1997) (74)
Cell surface antigens of human melanocytes and melanoma. Expression of adenosine deaminase binding protein is extinguished with melanocyte transformation (1988) (73)
Induction of IgG antibodies against GD3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. (1991) (73)
Immunity to cancer through immune recognition of altered self: studies with melanoma. (2003) (71)
National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992 (1993) (70)
Injection of DNA encoding granulocyte-macrophage colony-stimulating factor recruits dendritic cells for immune adjuvant effects. (1999) (68)
Temozolomide plus thalidomide in patients with advanced melanoma: results of a dose-finding trial. (2002) (67)
Anti‐melanoma effects of R24, a monoclonal antibody against GD3 ganglioside (1997) (67)
Serological survey of normal humans for natural antibody to cell surface antigens of melanoma. (1980) (66)
Class 1 (unique) tumor antigens of human melanoma. Identification of a 90,000 dalton cell surface glycoprotein by autologous antibody (1984) (66)
Peptide-Loaded Langerhans Cells, Despite Increased IL15 Secretion and T-Cell Activation In Vitro, Elicit Antitumor T-Cell Responses Comparable to Peptide-Loaded Monocyte-Derived Dendritic Cells In Vivo (2011) (66)
Reactivity of autologous CD4+ T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. (1995) (65)
Unraveling the complex relationship between cancer immunity and autoimmunity: lessons from melanoma and vitiligo. (2006) (64)
Serological response of melanoma patients to vaccines prepared from VSV lysates of autologous and allogeneic cultured melanoma cells (1985) (63)
A role for a melanosome transport signal in accessing the MHC class II presentation pathway and in eliciting CD4+ T cell responses. (1999) (62)
Alphavirus Replicon Particles Expressing TRP-2 Provide Potent Therapeutic Effect on Melanoma through Activation of Humoral and Cellular Immunity (2010) (61)
FAPalpha, a surface peptidase expressed during wound healing, is a tumor suppressor. (2004) (61)
FAPα, a surface peptidase expressed during wound healing, is a tumor suppressor (2004) (61)
Specificity analysis of human monoclonal antibodies reactive with cell surface and intracellular antigens. (1986) (60)
Comparison of Two Cancer Vaccines Targeting Tyrosinase: Plasmid DNA and Recombinant Alphavirus Replicon Particles (2005) (60)
Monoclonal antibodies: potential applications to the treatment of cancer. (1986) (60)
Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies. (1999) (59)
A Single-Institution Validation of the AJCC Staging System for Stage IV Melanoma (2007) (58)
Malignant transformation of human melanocytes: induction of a complete melanoma phenotype and genotype. (1992) (57)
Induction of autoantibodies to syngeneic prostate‐specific membrane antigen by xenogeneic vaccination (2005) (56)
Phase Ia trial of murine immunoglobulin A antitransferrin receptor antibody 42/6. (1995) (55)
Matrix Metalloproteinase-9 (MMP-9) polymorphisms in patients with cutaneous malignant melanoma (2007) (53)
INCREASED INCIDENCE OF MALIGNANT MELANOMA AFTER PEAKS OF SUNSPOT ACTIVITY (1978) (52)
Evaluation of Elispot assays: influence of method and operator on variability of results. (2004) (52)
Intradermal injection of granulocyte-macrophage colony-stimulating factor (GM-CSF) in patients with metastatic melanoma recruits dendritic cells. (1999) (51)
Strategies to overcome immune ignorance and tolerance. (2002) (51)
Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection (2010) (50)
Purification of an autoantigenic 75‐kDa human melanosomal glycoprotein (1991) (50)
Adjuvanticity of Plasmid DNA Encoding Cytokines Fused to Immunoglobulin Fc Domains (2006) (50)
Phase II study of temozolomide and thalidomide in patients with metastatic melanoma in the brain (2006) (48)
Priming for T-cell-mediated rejection of established tumors by cutaneous DNA immunization. (1997) (48)
Serological responses of melanoma patients to vaccines derived from allogeneic cultured melanoma cells (1983) (47)
Sorting and secretion of a melanosome membrane protein, gp75/TRP1. (1997) (46)
Xenogeneic DNA immunization in melanoma models for minimal residual disease. (2002) (46)
Identification of cancer-testis genes expressed by melanoma and soft tissue sarcoma using bioinformatics. (2005) (45)
Vaccinia Virus Subverts a Mitochondrial Antiviral Signaling Protein-Dependent Innate Immune Response in Keratinocytes through Its Double-Stranded RNA Binding Protein, E3 (2008) (45)
Distribution of the ganglioside GD3 in the human nervous system detected by R24 mouse monoclonal antibody (1984) (44)
Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma (1994) (44)
Assignment of the human TYRP (brown) locus to chromosome region 9p23 by nonradioactive in situ hybridization. (1992) (44)
A phase I study of anti‐GD3 ganglioside monoclonal antibody R24 and recombinant human macrophage‐colony stimulating factor in patients with metastatic melanoma (1995) (43)
Rejection of mouse melanoma elicited by local secretion of interleukin‐2: Implicating macrophages without T cells or natural killer cells in tumor rejection (1995) (43)
Paucity of functional T-cell memory to melanoma antigens in healthy donors and melanoma patients. (2000) (42)
Treatment with high dose mouse monoclonal (anti‐GD3) antibody R24 in patients with metastatic melanoma (1992) (42)
Phase II study of temozolomide plus pegylated interferon‐α‐2b for metastatic melanoma (2006) (41)
A T cell receptor associated with naturally occurring human tumor immunity (2007) (41)
Solar radiation and malignant melanoma of the skin. (1981) (40)
Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway (2011) (39)
Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma. (1997) (39)
Light chain variants of an IgG3 anti-GD3 monoclonal antibody and the relationship among avidity, effector functions, tumor targeting, and antitumor activity. (1990) (39)
Monoclonal antibody therapy of cancer. (1993) (38)
Stuck in the MUC on the long and winding road (1998) (38)
The Role of Homophilic Binding in Anti-tumor Antibody R24 Recognition of Molecular Surfaces (1999) (38)
Homophilic binding of mouse monoclonal antibodies against GD3 ganglioside. (1990) (36)
Increased proliferation, cytotoxicity, and gene expression after stimulation of human peripheral blood T lymphocytes through a surface ganglioside (GD3) (1994) (35)
Optimization and validation of a robust human T-cell culture method for monitoring phenotypic and polyfunctional antigen-specific CD4 and CD8 T-cell responses. (2009) (34)
Melanoma. Clinical practice guidelines in oncology. (2004) (34)
The role of the immune system in early epithelial carcinogenesis: B-ware the double-edged sword. (2005) (33)
GM-CSF DNA induces specific patterns of cytokines and chemokines in the skin: implications for DNA vaccines. (2002) (33)
Immunologic responses to xenogeneic tyrosinase DNA vaccine administered by electroporation in patients with malignant melanoma (2013) (33)
Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma. (2008) (33)
Two Distinct Categories of Focal Deletions in Cancer Genomes (2013) (32)
Granulocyte-macrophage colony-stimulating factor signals for increased glucose uptake in human melanoma cells. (1995) (32)
Innate Immune Response of Human Plasmacytoid Dendritic Cells to Poxvirus Infection Is Subverted by Vaccinia E3 via Its Z-DNA/RNA Binding Domain (2012) (31)
Selective expression of inhibitory Fcγ receptor by metastatic melanoma impairs tumor susceptibility to IgG‐dependent cellular response (2008) (31)
NCCN melanoma practice guidelines. National Comprehensive Cancer Network. (1998) (30)
Acute hepatic vein thrombosis occurring during therapy for hodgkin's disease. A case report (1979) (30)
Definition of tumor antigens suitable for vaccine construction. (1995) (30)
Melanocyte differentiation marker gp75, the brown locus protein, can be regulated independently of tyrosinase and pigmentation. (1995) (29)
Serological response of melanoma patients receiving melanoma cell vaccines. I. Autologous cultured melanoma cells (1982) (29)
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. (1992) (28)
Establishment and characterization of two human myeloma cell lines secreting kappa light chains. (1989) (28)
Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation. (2009) (28)
Phase I study of continuous-infusion recombinant macrophage colony-stimulating factor in patients with metastatic melanoma. (1996) (27)
Gangliosides of T lymphocytes: evidence for a role in T-cell activation. (1990) (26)
The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis (2004) (26)
Tumor endothelial marker 8 enhances tumor immunity in conjunction with immunization against differentiation Ag. (2007) (26)
Insect cells as HLA-restricted antigen-presenting cells for the IFN-γ Elispot assay (2000) (25)
CD8+ T-cell-dependent immunity following xenogeneic DNA immunization against CD20 in a tumor challenge model of B-cell lymphoma. (2005) (25)
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. (2006) (25)
Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. (2007) (25)
Antibody and CD8+ T Cell Responses against HER2/neu Required for Tumor Eradication after DNA Immunization with a Flt-3 Ligand Fusion Vaccine (2007) (25)
Non-antibody immunotherapy of cancer. (1993) (25)
Diverse roles of conserved asparagine-linked glycan sites on tyrosinase family glycoproteins. (2001) (24)
A phase II trial of high‐dose cisplatin and dacarbazine. Lack of efficacy of high‐dose, cisplatin‐based therapy for metastatic melanoma (1991) (23)
Tissue distribution of GD3 ganglioside detected by mouse monoclonal antibody R24. (1989) (23)
OX 40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis (2009) (23)
The cytoplasmic tail of the mouse brown locus product determines intracellular stability and export from the endoplasmic reticulum. (1998) (22)
Characterization of an Ig VH idiotope that results in specific homophilic binding and increased avidity for antigen. (1996) (22)
Medical treatment of metastatic melanoma. (1996) (21)
Differentiation antigens of melanoma and melanocytes. (1986) (21)
Phase 2 Study of the g209-2M Melanoma Peptide Vaccine and Low-Dose Interleukin-2 in Advanced Melanoma: Cancer and Leukemia Group B 509901 (2006) (20)
Induction of autoantibodies against tyrosinase-related proteins following DNA vaccination: unexpected reactivity to a protein paralogue. (2002) (19)
Mechanisms of immunization against cancer using chimeric antigens. (2008) (19)
Hemorrhagic tumor necrosis during a pilot trial of tumor necrosis factor-alpha and anti-GD3 ganglioside monoclonal antibody in patients with metastatic melanoma. (1994) (19)
Detection of Intra-Tumor Self Antigen Recognition during Melanoma Tumor Progression in Mice Using Advanced Multimode Confocal/Two Photon Microscope (2011) (18)
DNA Immunization against Tissue-Restricted Antigens Enhances Tumor Immunity after Allogeneic Hemopoietic Stem Cell Transplantation1 (2006) (18)
Recognition of Autoantigens by Patients with Melanoma (1993) (17)
Immune rejection of mouse tumors expressing mutated self. (2009) (17)
Current status of antitumor therapy with monoclonal antibodies. (1987) (16)
Melanoma: Clinical practice guidelines in oncology™ (2006) (16)
Mouse monoclonal IgG 3 antibody detecting GD 3 ganglioside : A phase I trial in patients with malignant melanoma ( complement activation / inflammation / immunotherapy ) (2003) (16)
Alternative roles for interferon-gamma in the immune response to DNA vaccines encoding related melanosomal antigens. (2001) (16)
Functional polymorphisms in the promoter regions of MMP2 and MMP3 are not associated with melanoma progression (2007) (15)
Estimates of stage‐specific survival are altered by changes in the 2002 American Joint Committee on Cancer staging system for melanoma (2006) (15)
Production and characterization of antibodies against human tyrosinase. (1994) (15)
On course for a cancer vaccine (1995) (14)
In vitro expansion of Ag-specific T cells by HLA-A*0201-transfected K562 cells for immune monitoring. (2006) (14)
Insect cells as HLA-restricted antigen-presenting cells for the IFN-gamma elispot assay. (2000) (14)
Combination of epitope-optimized DNA vaccination and passive infusion of monoclonal antibody against HER2/neu leads to breast tumor regression in mice. (2011) (13)
Vaccines and other adjuvant therapies for melanoma. (1998) (13)
Surface antigens of human melanoma cells cultured in serum-free medium: induction of expression of major histocompatibility complex class II antigens. (1988) (13)
Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent (2013) (12)
R24 anti‐GD3 ganglioside antibody can induce co‐stimulation and prevent the induction of alloantigen‐specific T cell clonal anergy (1996) (12)
Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2'-deoxycytidine or hydroxyurea: analysis and implications. (1988) (11)
Mouse monoclonal antibody detecting G(D3) ganglioside: A phase I trial in patients with malignant melanoma (1985) (11)
The Generation of Human Monoclonal Antibodies and Their Use in the Analysis of the Humoral Immune Response to Cancer (1985) (10)
Purification of human melanocytes by monoclonal antibody combined with Percoll gradients. (1982) (10)
Antigens recognized by autologous antibodies of patients with soft tissue sarcoma. (2005) (10)
Unconjugated Monoclonal Antibodies as Anticancer Agents (1991) (10)
The role of lipopolysaccharide in T-cell responses following DNA vaccination. (2003) (10)
A xenogeneic PSMA DNA vaccine for patients (pts) with non-castrate metastatic (NCMPC) and castrate metastatic prostate cancer (CMPC)—A phase I trial of proof of principle (2007) (10)
Melanoma and melanocytes: pigmentation, tumor progression, and the immune response to cancer. (1995) (10)
LIGHTing the way for tumor immunity (2004) (9)
The T Cell Cytolytic Molecules Fas Ligand and TRAIL, the Trafficking Molecules CCR9, β7 Integrin and PSGL-1, and the Immune Modulating Molecules OX40, CEACAM1, and CTLA4 Are Required for Thymic Graft-Versus-Host Disease (2008) (9)
Macrophage colony-stimulating factor: biological effects and potential applications for cancer therapy. (1991) (8)
Microenvironment and Immunology Monocytic CCR 2 þ Myeloid-Derived Suppressor Cells Promote Immune Escape by Limiting Activated CD 8 T-cell In fi ltration into the Tumor Microenvironment (2012) (8)
Phenotypic heterogeneity of melanoma. (1988) (8)
Langerhans-Type Dendritic Cells Genetically Modified to Express Full-Length Antigen Optimally Stimulate CTLs in a CD4-Dependent Manner1 (2006) (8)
Tumor endothelial marker 8 enhances tumor immunity in conjunction with immnization against differentiation Ag. (2007) (8)
Cell surface antigens of melanocytes and melanoma. (1985) (8)
Antigens of melanocytes and melanoma (1991) (8)
Treatment of human metastatic melanoma with mouse monoclonal antibodies against GD3 ganglioside. (1989) (8)
Analysis of hybridoma-exchange antibodies. (1982) (8)
Cutaneous Melanoma, 4th Edition (2005) (7)
Molecular abnormalities in the expression of HLA class‐I antigens by melanoma cells (1991) (7)
Three human cell surface antigen systems determined by genes on chromosome 12 (1984) (7)
Building a better monoclonal antibody. (1988) (7)
Assignment of the DPP4 gene encoding adenosine deaminase binding protein (CD26/dipeptidylpeptidase IV) to 2q23. (1994) (7)
Antigens Expressed by Melanoma and Melanocytes (1987) (7)
Solar cycles and malignant melanoma. (1979) (6)
Biological study of R24 mouse monoclonal antibody in patients undergoing thoracotomy for pulmonary metastases from soft tissue sarcoma. (1994) (6)
Development of effective vaccines for old mice in a tumor model. (2009) (6)
Myxoma Virus Induces Type I Interferon Production in Murine Plasmacytoid Dendritic Cells via a TLR9/MyD88-, IRF5/IRF7-, and IFNAR-Dependent Pathway (2011) (5)
Tumor immunology (1991) (5)
CD 8 + T-Cell – Dependent Immunity Following Xenogeneic DNA Immunization against CD 20 in a Tumor Challenge Model of B-Cell Lymphoma (2004) (5)
Mapping effector functions of a monoclonal antibody to GD3 by characterization of a mouse-human chimeric antibody (1994) (5)
Faculty Opinions recommendation of Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. (2007) (5)
Monoclonal antibody therapy. (1992) (5)
Faculty Opinions recommendation of Signals from the sympathetic nervous system regulate hematopoietic stem cell egress from bone marrow. (2006) (4)
The serological analysis of human cancer. Identification of differentiation antigens on melanoma and melanocytes. (1983) (4)
Monoclonal antibodies for the treatment of cancer: therapeutic strategies. (1989) (4)
Human monoclonal antibodies recognizing intermediate filament (IF) molecules (1984) (4)
Immunoperoxidase staining of early human melanoma colonies with monoclonal antibodies. A new method for in vitro antigenic-morphologic correlation. (1984) (3)
Monoclonal antibodies in the treatment of hematopoietic malignancies. (1988) (3)
Expression and modulation of class I and class II histocompatibility leukocyte antigens on human soft tissue sarcomas (1993) (3)
Current Status of the Search for Melanoma-Specific Antigens (1981) (3)
Melanoma in Connecticut. (1978) (3)
48 Phase I study of HSPPC-96 (oncophage®) vaccine in patients with completely resected pancreatic adenocarcinoma (2003) (3)
HDM 2 Protein Overexpression , but not Gene Amplification , is Related to Tumorigenesis of Cutaneous Melanoma 1 (2001) (2)
Chapter 36 – Molecular Biology of Melanoma (2008) (2)
Expression of epidermal growth factor receptor and transforming growth factor alpha in human myogenic sarcomas (1992) (2)
Identification of differentiation antigens of melanoma and melanocytes by mouse and human monoclonal antibodies. (1984) (2)
Phase II trial of cisplatin and etoposide in patients with metastatic melanoma (1991) (2)
Monoclonal antibody therapy for cancer. (1991) (2)
apoptosis in response to the combination of bortezomib and SAHA Myc regulates aggresome formation, the induction of Noxa, and (2013) (2)
Phase I & Ib Trials of Murine Tyrosinase ± Human GM‐CSF DNA Vaccination in Dogs with Advanced Malignant Melanoma (2005) (2)
Immunotherapy with monoclonal antibodies in metastatic melanoma (1992) (2)
DNA-Based Cancer Vaccines (2002) (2)
Solar radiation and cutaneous melanoma. (1982) (2)
Cyclophosphamide enhances the antitumor potency of GITR engagement by increasing oligoclonal cytotoxic T cell fitness (2021) (2)
Monoclonal antibody therapy of cancer. (1991) (1)
Abstract 4742: Anti-tyrosinase related protein 1 (TRP1) antibody combined with cyclophosphamide induces adaptive immunity against melanoma (2011) (1)
Analysis of the Humoral Immune Repertoire in Patients with Cancer (1987) (1)
Immune response of cancer patients: Analysis with human monoclonal antibodies (1984) (1)
Class ificat ion of Clear-Cel l Sarcoma as a Subtype of Melanoma by Genomic Profil ing (2003) (1)
Antibodies: A Laboratory Manual edited by Ed Harlo and David Lane, Cold Spring Harbor Laboratory, 1988. $50.00 (xiii + 726 pages) ISBN 0 87969 314 2 (1989) (1)
An agonist anti-GITR antibody enhances effector and memory CD8 T cell responses and tumor immunity following xenogeneic DNA immunization against melanoma (2005) (1)
Serological Dissection of Human Breast Cancer with Mouse and Human Monoclonal Antibodies (1985) (1)
Related to Tumorigenesis of Cutaneous Melanoma HDM 2 Protein Overexpression , but not Gene Amplification , is Updated (2001) (1)
Times are a changin': the era of peptide immunization begins. (1997) (1)
Phase II evaluation of chlorozotocin in patients with malignant melanoma. (1981) (1)
Antiviral T cell responses (2005) (1)
Xenogeneic Human Tyrosinase DNA Vaccination Induces Specific Immune Response in Dogs with Advanced Malignant Melanoma (2005) (1)
Cancer immunology (1993) (1)
Blockade of surface bound TGF-β on regulatory T cells abrogates suppression of effector T cell function within the tumor microenvironment (TUM2P.1015) (2015) (1)
Specific Active Immunization Against Cell Surface Antigens of Human Malignant Melanoma: Development of an Approach (1981) (0)
Abstract 1971: Concurrent loss of PTEN and RB is sufficient to confer BRAF independence in melanomas harboring V600E BRAF mutations (2010) (0)
Temozolomide Plus Thal idomide in Pat ients With Advanced Melanoma : Resul ts of a Dose-Finding Tria l (2002) (0)
Alphavirus replicon particles expressing melanocyte differentiation antigens are effective vaccines for melanoma (41.55) (2009) (0)
Phase II trial of N-methylformamide in patients with metastatic melanoma (1991) (0)
Erratum (2005) (0)
The T Cell Cytolytic Molecules Fas Ligand And Trail, The Trafficking Molecules CCR9, β7 Integrin And PSGL1, And The Immune Modulating Molecules OX40 And Ceacam1 Are Required For Thymic Graft-Versus-Host Disease (2009) (0)
Classification o f C lear-Cell S arcoma a s a S ubtype o f M elanoma by G enomic P rofiling (2003) (0)
Faculty Opinions recommendation of Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. (2004) (0)
Treatment of Malignant Melanoma with a Mouse Monoclonal IgG3 Antibody Detecting the Ganglioside GD3 (1986) (0)
B cell deficient mice reject B16 melanoma via T cell mediated immunity that is not associated with autoimmunity (2000) (0)
Faculty Opinions recommendation of Initial T cell frequency dictates memory CD8+ T cell lineage commitment. (2005) (0)
Antibody Reactivity to Cell Surface and IntraceUular Antigens (2003) (0)
Faculty Opinions recommendation of DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. (2007) (0)
DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mice Following Sub-Lethal Irradiation and Immune Reconstitution. (2004) (0)
Agonist anti-GITR antibody induces CD8 T cell-mediated tumor rejection (2007) (0)
ADENOSINE DEAMINASE EXPRESSION BY MELANOCYTES (2003) (0)
CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response (2009) (0)
Xenogeneic DNA vaccination prevents metastasis in a melanoma model of minimal residual disease (2000) (0)
Abstract B87: Genomic complexity and BRAF/MEK‐dependence in V600E BRAF mutant melanoma (2009) (0)
Monoclonal antibody therapy of cancer. (1991) (0)
DNA Immunization Against Melanoma Antigens Enhances Tumor Immunity in Mouse Models of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). (2004) (0)
Long-Term Survival of Dogs with Advanced Malignant Melanoma after DNA Vaccination with Xenogeneic Human Tyrosinase : A Phase I Trial 1 (2003) (0)
Thirty Years of Advances in Melanoma (2009) (0)
TGF-β dependent suppression of effector T cell function within the tumor microenvironment (P2033) (2013) (0)
Stage specific survival is altered by the changes in the 2002 AJCC staging for melanoma (2005) (0)
Milieu Is Right Regulatory T Cell Expansion if the Cytokine Cutting Edge: OX40 Agonists Can Drive (2009) (0)
Inflammation and immunity: approaches to immunotherapy in melanoma (1993) (0)
Faculty Opinions recommendation of Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. (2005) (0)
Chapter 17 Human Monoclonal Antibodies Humoral Immune Response in Patients with (1985) (0)
Effect of self antigen specific CD4+ T cell precursor frequency on the anti-tumor immune response: Implications for adoptive T cell therapy (P2040) (2013) (0)
Faculty Opinions recommendation of Elucidating the autoimmune and antitumor effector mechanisms of a treatment based on cytotoxic T lymphocyte antigen-4 blockade in combination with a B16 melanoma vaccine: comparison of prophylaxis and therapy. (2001) (0)
Synergistic Tumor Immunity Induced by Chemotherapy and Agonist Anti-GITR Antibody. (2007) (0)
Monoclonal antibodies and immobilized antibodies (1987) (0)
A role for the GITR pathway in anaphylaxis (P4326) (2013) (0)
337 Evaluation of the immunogenicity of selected doses of BEC2 plus BCG after initial therapy for small cell lung cancer and report of long survival of immunized patients (1997) (0)
Faculty Opinions recommendation of Slug Antagonizes p53-Mediated Apoptosis of Hematopoietic Progenitors by Repressing puma (2005) (0)
Immunologic Study of Tumors in Mouse Models (2004) (0)
Melanoma tumor antigen and autologous antibody (1986) (0)
Differentiation Antigen Immunization Against a Tumor Cancer Immunity After Xenogeneic DNA A Single Heteroclitic Epitope Determines (2003) (0)
Xenogeneic immunization with tyrosinase DNA vaccines: results from clinical trials in humans and dogs (2006) (0)
XENOGENEIC DNA IMMUNIZATION WITH TYROSINASE RELATED PROTEIN-2 BREAKS TOLERANCE: DEFINING SPECIFIC MECHANISMS IN AUTOIMMUNITY AND TUMOR IMMUNITY (1999) (0)
Blockade of surface bound TGF-β abrogates Treg suppression of effector T cell function within the tumor microenvironment (2014) (0)
Biologic basis for monoclonal antibodies in cancer treatment (1987) (0)
Chapter 13 The biology of human melanoma (1996) (0)
Gp75 as a tumor vaccine against melanomas (1991) (0)
FAB FRAGMENT FROM MURINE ASCITES (1999) (0)
Genetic cancer vaccines: 488 (1997) (0)
Antibody and CD 8 + TCell Responses against HER 2 / neu Required for Tumor Eradication after DNA Immunizationwith a Flt-3 Ligand FusionVaccine (2007) (0)
791 Immune checkpoint blockade enhances cyclophosphamide induced anti-tumor immunity in a preclinical melanoma model (2022) (0)
Monoclonal antibody therapy of cancer. (1991) (0)
Abstract 4167: Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model (2022) (0)
Blockade of Treg derived TGF-β abrogates suppression of effector T cell function within the tumor microenvironment (2013) (0)
Antitumor Immunity Differentiation Antigens and Enhances Tolerance/Ignorance to Melanoma Family Related Gene Activation Overcomes Glucocorticoid-Induced TNF Receptor (2006) (0)
Agonist anti-GITR antibody synergizes with cyclophosphamide (CTX) to induce tumor immunity (2008) (0)
Phase I II M ulticenter R andomized T rial o f t he D artmouth Regimen V ersus D acarbazine i n P atients With M etastatic M elanoma (1999) (0)
Abstract #5657: Agonist anti-GITR monoclonal antibody targets both regulatory and effector T cells to induce tumor immunity (2009) (0)
The T Cell Cytolytic Molecules FasL and TRAIL are Required for Thymic GVHD (141.14) (2009) (0)
Cell surface antigens of human astrocytoma defined by mouse monoclonal antibodies : Identification of astrocytoma subsets ( hybridoma / differentiation antigens / glial fibrillary acidic protein ) (2003) (0)
Faculty Opinions recommendation of In vivo dynamics of antigen-specific regulatory T cells not predicted from behavior in vitro. (2003) (0)
Chromosomal instability in mouse metastatic pancreatic cancer— it's Kras and Tp53 after all (2005) (0)
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in β2 μmRNA: 38 (1993) (0)
Genetic variation at MC1R, GSTT1, and GSTM1 may increase risk for melanoma (1999) (0)
Cancer Immunity, Vol. 5, p. 2 (1 February 2005) (2005) (0)
Abstract A43: Therapeutic efficacy of antitumor monoclonal antibodies combined with chemotherapy depends on innate immunity and NK1.1- innate lymphoid cells. (2013) (0)
TransplantationAllogeneic Hemopoietic Stem Cell Antigens Enhances Tumor Immunity after DNA Immunization against Tissue-Restricted (2006) (0)
MULTIPLE KINASE INVOLVEMENT IN THE ACTIVATION OF HUMAN PERIPHERAL BLOOD T LYMPHOCYTES WITH AN ANTI-GANGLIOSIDE (GD3) MONOCLONAL ANTIBODY (mAb) (1993) (0)
In Vitro Expansion of Antigen-Specific Cytotoxic T Lymphocytes by HLA-A*0201 Transfected K562 for Monitoring of T-cell Responses (2005) (0)
A Perspective on Cancer Immunology and Immunotherapy (2007) (0)
Raising Monoclonal Antibodies Monoclonal Antibody-Based Therapy of Cancer Edited by Michael L. Grossbard New York: Marcel Dekker (1998). 464 pp. $185.00 (1999) (0)
CD8+ T cell precursor frequency determines the quality of the anti-tumor immune response (40.33) (2009) (0)
Patent Number : 5 , 389 , 530 45 Date of Patent : Feb . 14 , 1995 GD 3 ganglioside : A phase I trail . . . melanoma ' (2017) (0)
Faculty Opinions recommendation of Lymphangiogenic gene therapy with minimal blood vascular side effects. (2002) (0)
Cell-Mediated Immunity to Cancer (2002) (0)
Cancer Immunity, Vol. 5, p. 4 (4 March 2005) (2005) (0)
Transformation of human melanocytes in vitro (1986) (0)
Phase I I S tudy o f T emozolomide P lus T halidomide f or t he Treatment o f M etastatic M elanoma (2003) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Alan N. Houghton?

Alan N. Houghton is affiliated with the following schools: